Categories AlphaGraphs, Earnings, Finance, LATEST

Intuit (INTU) Q3 results miss estimates; revenue up 39%

Financial technology company Intuit Inc. (NASDAQ: INTU) reported higher earnings and revenues for the third quarter of 2021. But the results missed Wall Street’s estimates.

Intuit Q3 2021 earnings infographic

At $4.17 billion, third-quarter revenues were up 39% from the year-ago period but below experts’ projection. The topline benefitted from double-digit growth across all business segments.

As a result, adjusted earnings jumped to $6.07 per share from $4.49 per share in the third quarter of 2020 but missed the consensus forecast. Net income, including one-off items, was $1.46 billion or $5.30 per share, compared to $1.1 billion or $4.11 per share last year.


Read management/analysts’ comments on Intuit’s Q3 results


Intuit’s shares rose to an all-time high this week, after gaining 6% since the beginning of the year. The stock closed Tuesday’s trading lower.

Prior Performance

  • Intuit reports Q4 2020 earnings results
  • During the first half of the fiscal year we grew total company revenue 14 percent, and we saw this momentum continue into the beginning of the third quarter. However,

_________________________________________________________________________________________________________________

Stocks you may like:

Bank of America (BAC) Stock

Wells Fargo (WFC) Stock

JPMorgan Chase (JPM) Stock

Citigroup (C) Stock

Goldman Sachs (GS) Stock

Morgan Stanley (MS) Stock

_________________________________________________________________________________________________________________

Most Popular

Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results

DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line

Macy’s (M): A few points to consider if you have an eye on this retailer

Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit

Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top